Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Status:
Completed
Trial end date:
2013-05-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients
with melanoma receiving hydroxychloroquine may help doctors understand the effect of
hydroxychloroquine on biomarkers.
PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage III
or stage IV melanoma that can be removed by surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey